CLINICAL TRIALS PROFILE FOR YERVOY
✉ Email this page to a colleague
All Clinical Trials for YERVOY
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | Medarex | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | U.S. Army Medical Research Acquisition Activity | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for YERVOY
Condition Name
Clinical Trial Locations for YERVOY
Trials by Country
Clinical Trial Progress for YERVOY
Clinical Trial Phase
Clinical Trial Sponsors for YERVOY
Sponsor Name
